Article Sidebar

PDF
Issue: No. 90 (2025): Kỷ niệm 10 năm thành lập Tạp chí Y Dược học Cần Thơ 2015-2025
Section: Article
DOI: 10.58490/ctump.2025i90.3153
Date Published: 25/08/2025
Views 15
Downloads 13
How to Cite
Nguyen, M. N., Le, M. L., Nguyen, P. T., & Truong, T. N. (2025). ABSTRACT EVALUATION THE OUTCOMES OF BEVACIZUMAB TREATMENT FOR DIABETIC RETINOPATHY AND ITS RELATED FACTORS AT CAN THO GENERAL HOSPITAL IN 2023-2024. Cantho Journal of Medicine and Pharmacy, 90, 23-29. https://doi.org/10.58490/ctump.2025i90.3153

ABSTRACT EVALUATION THE OUTCOMES OF BEVACIZUMAB TREATMENT FOR DIABETIC RETINOPATHY AND ITS RELATED FACTORS AT CAN THO GENERAL HOSPITAL IN 2023-2024

Minh Nhut Nguyen1, Minh Ly Le2, Phuoc Thien Nguyen1, Thanh Nam Truong2,
1 Can Tho General Hospital
2 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Diabetic retinopathy is the leading cause of vision loss in diabetic patients. Bevacizumab is used to regress neovascularization in proliferative diabetic retinopathy. Objectives: Determine the successful treatment rate of Bevacizumab and some factors related to the treatment outcomes of diabetic retinopathy at Can Tho City General Hospital in 2023-2024. Materials and Methods: A non-randomized, non-controlled clinical intervention study was conducted on 60 patients with diabetic retinopathy. Patients were treated with intraocular Bevacizumab injection and monthly monitoring and evaluation for 6 months on visual acuity, ophthalmoscopy images, retinal tomography, retinal thickness, blood glucose, HbA1C, and total cholesterol. Results: The overall mean age of the 60 patients was 61.1±11.9 years old. Men constituted a larger share (56.7%) than women (43.3%). The successful treatment rate was 85%. After 6 months of treatment, the level of fair and good vision increased, accounting for 40% and 48.3%, respectively. Regarding complications, 16.7% of patients had pain and 8.3% had conjunctival hemorrhage. Some factors related to successful treatment results include: Duration of diabetes 5-10 years (p=0.03); ophthalmoscopic lesions (p=0.02); Damage via retinal tomography (p=0.001); retinal thickness <250 μm (p=0.001); Blood cholesterol (p=0.004). Conclusion: Bevacizumab achieved an 85% successful clinical outcome in treating diabetic retinopathy and can continue per treatment protocol and indication. 

Keywords

Bevacizumab, diabetic retinopathy, Can Tho

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

References

1. Lê Thị Kim Minh, Võ Lê Ngọc Trúc, Võ Văn Tân, Tạ Văn Trầm. Tình hình bệnh lý võng mạc đái tháo đường và các yếu tố liên quan tại tỉnh Tiền Giang năm 2020. Tạp chí Đái tháo đường và Nội tiết Việt Nam. 2021, 46, 117-122, doi:10.47122/vjde.2021.46.11.
2. Alves A.D.C.S., Bruinsmann F.A., Guterres S.S., Pohlmann A.R. Organic nanocarriers for bevacizumab delivery: An overview of development, characterization and applications. Molecules. 2021. 26(14), 4127, doi: 10.3390/molecules26144127.
3. Nguyễn Như Quân. Nghiên cứu ứng dụng tiêm Bevacizumab vào buồng dịch kính trong điều trị phù hoàng điểm đái tháo đường. Luận án Tiến sĩ Y học. Đại học Y Dược TP. Hồ Chí Minh. 2019.
4. Sabanayagam C., Banu R., Chee M.L., Lee R., Wang Y.X., et al. Incidence and progression of diabetic retinopathy: A systematic review. The lancet Diabetes & endocrinology. 2019. 7(2), 140-149, doi: 10.1016/S2213-8587(18)30128-1.
5. Weinstein O., Abu Tailakh M., Lifshitz T., Novack V., Levy J. Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. European Journal of Ophthalmology. 2020, 30(1), 66-71, doi: 10.1177/1120672118823128.
6. Dervenis P., Dervenis N., Steel D., Sandinha T., Tranos P., et al. Intravitreal bevacizumab prior to vitrectomy for proliferative diabetic retinopathy: A systematic review. Therapeutic Advances in Ophthalmology. 2021. 13, 25158414211059256, doi: 10.1177/25158414211059256.
7. Avery R.L., Pearlman J., Pieramici D.J., Rabena M.D., Castellarin A.A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006. 113(10), 1695-1705, doi: 10.1016/j.ophtha.2006.05.064.
8. Al-Debasi T., Al-Bekairy A., Al-Katheri A., Al Harbi S., Mansour M. Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Saudi Journal of Ophthalmology. 2017. 31(2), 99-105, doi: 10.1016/j.sjopt.2017.02.008.
9. Nguyễn Diệu Linh. Nghiên cứu sử dụng thuốc Bevacizumab tiêm nội nhãn phối hợp cắt dịch kính điều trị bệnh võng mạc đái tháo đường giai đoạn tăng sinh có biến chứng xuất huyết dịch kính. Luận án Tiến sĩ, Đại học Y Hà Nội. 2019.
10. Lu J., Ma X., Zhou J., Zhang L., Mo Y. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes care. 2018. 41(11), 2370-2376, doi: 10.2337/dc18-1131.
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998, 317(7160), 703-13, doi: 10.1136/bmj.317.7160.703.
12. Ting Daniel S., Cheung G.C., Wong T.Y. Diabetic retinopathy: Global prevalence, major risk factors, screening practices and public health challenges: A review. Clin Exp Ophthalmol. 2016. 44(4), 260-77, doi: 10.1111/ceo.12696.
13. Nguyễn Thị Lan Anh. Nghiên cứu các hình thái lâm sàng và một số yếu tố nguy cơ của bệnh võng mạc đái tháo đường tại Bệnh viện E Trung ương, Luận văn Bác sĩ Chuyên khoa II, Đại học Y Hà Nội. 2017, doi: 10.51298/vmj.v533i1.7710.